Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24036
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsiara, S. N.en
dc.contributor.authorKapsali, E.en
dc.contributor.authorChristou, L.en
dc.contributor.authorPanteli, A.en
dc.contributor.authorPritsivelis, N.en
dc.contributor.authorBourantas, K. L.en
dc.date.accessioned2015-11-24T19:37:29Z-
dc.date.available2015-11-24T19:37:29Z-
dc.identifier.issn0902-4441-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24036-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectDexamethasone/administration & dosage/adverse effectsen
dc.subjectDoxorubicin/administration & dosage/adverse effectsen
dc.subjectDrug Carriersen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectImmunoelectrophoresisen
dc.subjectLiposomesen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMultiple Myeloma/blood/*drug therapyen
dc.subjectVincristine/administration & dosage/adverse effectsen
dc.titleAdministration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary dataen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10966172-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1034/j.1600-0609.2000.90145.x/asset/j.1600-0609.2000.90145.x.pdf?v=1&t=h2boys2p&s=9e53a2d33d1de1caca76260ec51e224f1e93f854-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2000-
heal.abstractFor elderly patients with multiple myeloma (MM), conventional melphalan and prednisone (MP) therapy has been the treatment of choice; the vincristine, doxorubicin and dexamethasone (VAD) regimen is preferred for younger patients who also receive high-dose melphalan in combination with autologous or allogeneic bone marrow transplantation (BMT). Although survival time is similar in both the MP and VAD regimens, the continuous infusion of doxorubicin which the latter treatment entails constitutes a disadvantage along with the 4-day hospitalization required. Doxorubicin also induces cardiotoxicity, particularly in the elderly. A modified form of VAD therapy includes liposomal doxorubicin (Caelyx) (40 mg/m2 for 1 d) [corrected], oncovin (2 mg for 1 d) and dexamethasone 40 mg for 4 d per os. Doxorubicin encapsulated with liposomes has less cardiotoxicity, is more efficient and has fewer side effects than conventional doxorubicin, and it can be administered on an outpatient basis: dexamethasone can be given orally and vincristine in bolus infusion. In order to estimate its efficacy and tolerability, we administered this regimen to 12 patients (first-line treatment in 6 patients, salvage therapy in 6 patients). All patients exhibited good tolerance to liposomal doxorubicin with no severe side effects. Eight patients achieved complete hematological remission and three partial response. One patient died before completing the treatment. In conclusion, compared to other therapies, this modified VAD regimen containing liposomal doxorubicin can be more easily administered to MM patients, without severe side effects and with increased full remission rates, almost similar to those with the conventional VAD treatment.en
heal.journalNameEur J Haematolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Tsiara-2000-Administration of a.pdf62.26 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons